Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02644941 · ClinicalTrials.gov registry record · Phase 3
Comparison of the Human Acellular Vessel (HAV) With ePTFE Grafts as Conduits for Hemodialysis
A Phase 3 study, sponsored by Humacyte.
- Completed
- Registry status
- Phase 3
- Development phase
- 355
- Enrollment target
NCT02644941: Completed Phase 3 study, sponsored by Humacyte.
NCT02644941 is a Phase 3 study that has completed, run by Humacyte. The registered enrollment target is 355 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (54% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02644941, a Phase 3 study, has completed, sponsored by Humacyte.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 355 participants
- Enrollment target
Study Summary
The main purpose of this study is to compare the Human Acellular Vessel (HAV) with ePTFE grafts when used for hemodialysis access.
Primary Outcome
1. Defined as 'the interval from the time of access placement until access abandonment', i.e., patent with or without interventions (Sidawy et al. 2002). 2. "Abandonment" defined as no remaining segment of the study conduit was incorporated into the vascular access circuit used for dialysis (conversely, if some portion of the study conduit was still being used for dialysis it was not considered abandoned).
Interventions
- BIOLOGICAL Human Acellular Vessel (HAV)
- DEVICE ePTFE graft
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 355 participants |
| Start Date | 2016-05-24 |
| Est. Completion | 2023-09 |
| Phase | Phase 3 |
What the finished NCT02644941 record still lists
NCT02644941 is an interventional study that assigns participants to a tested intervention. The registered 355 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (54% lower).
The record links to 0 conditions, and to 2 interventions - of which Human Acellular Vessel (HAV) is the first listed.
NCT02644941 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02644941 about?
NCT02644941 is a clinical study titled "Comparison of the Human Acellular Vessel (HAV) With ePTFE Grafts as Conduits for Hemodialysis". The main purpose of this study is to compare the Human Acellular Vessel (HAV) with ePTFE grafts when used for hemodialysis access.
What is the current status of trial NCT02644941?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 355 participants. The study started on 2016-05-24. Estimated completion is 2023-09.
What interventions are being tested in trial NCT02644941?
The interventions under investigation include: Human Acellular Vessel (HAV) (BIOLOGICAL), ePTFE graft (DEVICE).
Who is sponsoring clinical trial NCT02644941?
This trial is sponsored by Humacyte, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02644941's enrollment target sits among peer trials
355 1025th of 2000 higher than 975 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07133308 · 355 participants · Phase 3
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata
- NCT07193511 · 355 participants · Phase 1
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
- NCT06077838 · 356 participants · NA
RELAXaHEAD for Headache Patients (Phase III)
- NCT06293469 · 356 participants · NA
Accelerated Flap Coverage in Severe Lower Extremity Trauma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI